Latest News

Archive 2009

2009
12.29.09	PharmaGap Announces $608,800 Private Placement
12.02.09	PharmaGap Provides Corporate Update & Announces Financing
10.27.09	PharmaGap Reports That GAP-107B8 Showed Strong and Consistent Anti-Cancer Activity in a Wide Range of Cancers in NCI Test
10.21.09	PharmaGap Announces Completion of Securities Lending Arrangements with Stormont
10.20.09	PharmaGap Advises That NCI Test Results Are Completed and Expected To Be Provided To The Company Shortly
09.17.09	Ottawa Hospital Research Institute Testing of PharmaGap’s Novel Cancer Drug Formally Underway
09.02.09	Results from NCI Five-Dose Study of PharmaGap Cancer Drug Expected Late September
08.24.09	PharmaGap Releases Compelling Results for GAP-107B8 from the U.S. National Cancer Institute
08.13.09	PharmaGap Advised By U.S. National Cancer Institute Of Positive Results Of Testing for the Company’s Lead Cancer Drug GAP-107B8
08.06.09	PharmaGap Updates Guidance On Anticipated Timing Of Results From Testing At National Cancer Institute
08.06.09	PharmaGap Releases Results of Initial Testing For Novel Cancer Drug Compound at the Ottawa Hospital Research Institute
07.17.09	PharmaGap Provides Guidance on Cancer Drug Testing Timetable
07.16.09	PharmaGap Raises Additional Equity Financing
06.23.09	PharmaGap Announces Agreement for the Issuance of Shares to National Research Council of Canada
06.17.09	PharmaGap Announces Completion of $861,920 Private Placement of Shares and Warrants
05.07.09	PharmaGap Provides Guidance on Timing of Testing at National Cancer Institute
05.06.09	PharmaGap Provides Drug Compound to Ottawa Hospital Research Institute to Begin Test Program in Ovarian Cancer
05.01.09	PharmaGap Ships Cancer Drug to National Cancer Institute for Testing
03.24.09	PharmaGap Announces Testing Program for Novel Cancer Drug Compound at the Ottawa Health Research Institute
03.16.09	PharmaGap and MD Biosciences Announce a Collaboration to Pursue Development of a Novel PKC Theta Inhibitor for Inflammatory and Neurological Diseases
02.27.09	PharmaGap Finalizes Conversion of Convertible Debentures
02.19.09	PharmaGap Announces Option Grants to Officers and Directors
02.12.09	PharmaGap lead drug to be tested at the U.S. National Cancer Institute
02.11.09	PharmaGap Announces Receipt of Notice of Conversion of Convertible Debentures